These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 29279332)

  • 1. Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma.
    Huynh M; Pak C; Markovina S; Callander NS; Chng KS; Wuerzberger-Davis SM; Bakshi DD; Kink JA; Hematti P; Hope C; Asimakopoulos F; Rui L; Miyamoto S
    J Biol Chem; 2018 Feb; 293(7):2452-2465. PubMed ID: 29279332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance.
    Mark C; Warrick J; Callander NS; Hematti P; Miyamoto S
    Mol Cancer Res; 2022 Sep; 20(9):1456-1466. PubMed ID: 35604822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.
    Markovina S; Callander NS; O'Connor SL; Kim J; Werndli JE; Raschko M; Leith CP; Kahl BS; Kim K; Miyamoto S
    Mol Cancer Res; 2008 Aug; 6(8):1356-64. PubMed ID: 18708367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells.
    Markovina S; Callander NS; O'Connor SL; Xu G; Shi Y; Leith CP; Kim K; Trivedi P; Kim J; Hematti P; Miyamoto S
    Mol Cancer; 2010 Jul; 9():176. PubMed ID: 20604947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
    Hideshima T; Ikeda H; Chauhan D; Okawa Y; Raje N; Podar K; Mitsiades C; Munshi NC; Richardson PG; Carrasco RD; Anderson KC
    Blood; 2009 Jul; 114(5):1046-52. PubMed ID: 19436050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
    Yang L; Chen J; Han X; Zhang E; Huang X; Guo X; Chen Q; Wu W; Zheng G; He D; Zhao Y; Yang Y; He J; Cai Z
    Protein Cell; 2018 Sep; 9(9):770-784. PubMed ID: 29441489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
    Berenson JR; Ma HM; Vescio R
    Semin Oncol; 2001 Dec; 28(6):626-33. PubMed ID: 11740821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
    Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
    Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing of SENP2 in Multiple Myeloma Induces Bortezomib Resistance by Activating NF-κB Through the Modulation of IκBα Sumoylation.
    Xie H; Gu Y; Wang W; Wang X; Ye X; Xin C; Lu M; Reddy BA; Shu P
    Sci Rep; 2020 Jan; 10(1):766. PubMed ID: 31964975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.
    Fabre C; Mimura N; Bobb K; Kong SY; Gorgun G; Cirstea D; Hu Y; Minami J; Ohguchi H; Zhang J; Meshulam J; Carrasco RD; Tai YT; Richardson PG; Hideshima T; Anderson KC
    Clin Cancer Res; 2012 Sep; 18(17):4669-81. PubMed ID: 22806876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.
    Zhao Y; Zhang K; Li G; Zhang X; Shi D
    PLoS One; 2015; 10(5):e0127334. PubMed ID: 25973846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ectopic CH60 mediates HAPLN1-induced cell survival signaling in multiple myeloma.
    De Bakshi D; Chen YC; Wuerzberger-Davis SM; Ma M; Waters BJ; Li L; Suzuki A; Miyamoto S
    Life Sci Alliance; 2023 Mar; 6(3):. PubMed ID: 36625202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
    Ma MH; Yang HH; Parker K; Manyak S; Friedman JM; Altamirano C; Wu ZQ; Borad MJ; Frantzen M; Roussos E; Neeser J; Mikail A; Adams J; Sjak-Shie N; Vescio RA; Berenson JR
    Clin Cancer Res; 2003 Mar; 9(3):1136-44. PubMed ID: 12631619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
    Yang DT; Young KH; Kahl BS; Markovina S; Miyamoto S
    Mol Cancer; 2008 May; 7():40. PubMed ID: 18489772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.
    Murray MY; Zaitseva L; Auger MJ; Craig JI; MacEwan DJ; Rushworth SA; Bowles KM
    Cell Cycle; 2015; 14(14):2367-75. PubMed ID: 25565020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NF-kappa B as a therapeutic target in multiple myeloma.
    Hideshima T; Chauhan D; Richardson P; Mitsiades C; Mitsiades N; Hayashi T; Munshi N; Dang L; Castro A; Palombella V; Adams J; Anderson KC
    J Biol Chem; 2002 May; 277(19):16639-47. PubMed ID: 11872748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DANFIN functions as an inhibitor of transcription factor NF-κB and potentiates the antitumor effect of bortezomib in multiple myeloma.
    Uematsu A; Kido K; Manabe E; Takeda H; Takahashi H; Hayashi M; Imai Y; Sawasaki T
    Biochem Biophys Res Commun; 2018 Jan; 495(3):2289-2295. PubMed ID: 29284118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
    Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.